Form 4 for ADMA ADMA BIOLOGICS, INC.
Accepted 2024-08-30 00:00:00 ET · period of report 2024-08-30 · accession 0001140361-24-039822 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| D | 2024-08-30 | 2024-08-30 | ADMA | Kestenberg-Messina Kaitlin M. | COO, SVP, Compliance | S - Sale+OE | $16.90 | -24.1K | 449.1K | -5% | -$408.1K |
| DM | 2024-08-30 | 2024-08-30 | ADMA | Kestenberg-Messina Kaitlin M. | COO, SVP, Compliance | M - OptEx | $3.87 | +24.1K | 473.2K | +5% | +$93.5K |
| DM | 2024-08-30 | 2024-08-30 | ADMA | Kestenberg-Messina Kaitlin M. | COO, SVP, Compliance | M - OptEx | $3.87 | -24.1K | 0 | -100% | -$93.5K |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2024-08-30 | S | D | 24,150 | $16.90 | 449,088 | D | — | — | (F1) The price reported in Column 4 is the weighted average price. These shares were sold in multiple transactions at prices ranging from $16.72 to $17.02. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer or a security holder of the Issuer, full information regarding the number of shares sold at each separate price. (F2) Includes, as of the transaction date (i) 192,320 unvested RSUs granted on April 1, 2024, that will vest in equal quarterly installments on each annual anniversary of the date of grant, over four years, subject to the reporting person's continued service as of the applicable vesting date; (ii) 22,500 unvested RSUs granted on July 24, 2023, that will vest in equal quarterly installments on each annual anniversary of the date of grant, over four years, subject to the reporting person's continued service as of the applicable vesting date; (iii) 71,250 unvested RSUs granted on March 6, 2023, that will vest in equal quarterly installments on each annual anniversary of the date of grant, over four years, subject to the reporting person's continued service as of the applicable vesting date; (iv) 20,000 unvested RSUs granted on March 7, 2022, that will vest in equal quarterly installments on each annual anniversary of the date of grant, over four years, subject to (F3) (continued from footnote 2) the reporting person's continued service as of the applicable vesting date; (v) 12,500 unvested RSUs granted on September 28, 2021, which are the remaining unvested RSUs of the 100,000 RSUs granted on September 28, 2021 which vest on a schedule of 50% vesting on December 31, 2022 and the remaining vesting quarterly from March 31, 2023 to December 31, 2024, subject to the reporting person's continued service as of the applicable vesting date; (vi) 5,000 unvested RSUs granted on February 25, 2021, that will vest in equal quarterly installments on each annual anniversary of the date of grant, over four years, subject to the reporting person's continued service as of the applicable vesting date; and (vii) 125,518 shares of common stock owned by the reporting person, which reflects the prior net settlement upon vesting of previously granted RSUs after the withholding of shares to cover applicable taxes. |
| 2 | Common | Common Stock | 2024-08-30 | M | A | 4,375 | $2.59 | 461,588 | D | — | — | |
| 3 | Common | Common Stock | 2024-08-30 | M | A | 6,650 | $5.94 | 468,238 | D | — | — | |
| 4 | Common | Common Stock | 2024-08-30 | M | A | 8,125 | $2.35 | 457,213 | D | — | — | |
| 5 | Common | Common Stock | 2024-08-30 | M | A | 5,000 | $4.72 | 473,238 | D | — | — | |
| 6 | Derivative | Common Stock | 2024-08-30 | M | D | 5,000 | $4.72 | 0 | D | $4.72 · — to 2028-05-03 | 5,000 Common Stock | (F7) These options were granted on May 3, 2018 and are fully vested. |
| 7 | Derivative | Common Stock | 2024-08-30 | M | D | 4,375 | $2.59 | 0 | D | $2.59 · — to 2030-03-10 | 4,375 Common Stock | (F5) These options were granted on March 10, 2020 and are fully vested. |
| 8 | Derivative | Common Stock | 2024-08-30 | M | D | 8,125 | $2.35 | 3,750 | D | $2.35 · — to 2031-02-25 | 8,125 Common Stock | (F4) These options were granted on February 25, 2021 and will vest over four years with 25% of the shares of common stock underlying the options vesting on the one-year anniversary of the date of grant and the remaining 75% of such shares vesting monthly in equal installments over the next three years thereafter, subject to the reporting person's continued service as of the applicable vesting date, and will become fully vested on February 25, 2025. |
| 9 | Derivative | Common Stock | 2024-08-30 | M | D | 6,650 | $5.94 | 0 | D | $5.94 · — to 2028-10-09 | 6,650 Common Stock | (F6) These options were granted on October 9, 2018 and are fully vested. |